# Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer's disease to individuals with MCI or early AD in the general population

Jacqueline J. Claus<sup>1,2</sup>, Ilse vom Hofe<sup>1</sup>, Annekee van Ijlzinga Veenstra<sup>1</sup>, Silvan Licher<sup>1,3</sup>, Harro Seelaar<sup>4</sup>, Frank J. de Jong<sup>4</sup>, Julia Neitzel<sup>1,2</sup>, Meike W. Vernooij<sup>1,2</sup>, M. Arfan Ikram<sup>1</sup>, Frank J. Wolters<sup>1,2</sup>

- 1. Dept. of Epidemiology, Erasmus MC, Rotterdam, the Netherlands
- 2. Dept. of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands
- 3. Dept. of General Practice, Erasmus MC, Rotterdam, the Netherlands
- 4. Dept. of Neurology, Erasmus MC, Rotterdam, the Netherlands

# **Corresponding Author:**

Frank J. Wolters, MD, PhD Department of Epidemiology, Erasmus MC PO Box 2040, Rotterdam 3000CA, the Netherlands Tel +31 10 7043488, Email: <u>f.j.wolters@erasmusmc.nl</u>

Key words: amyloid, clinical trials, monoclonal antibodies, Alzheimer's disease, generalizability

Manuscript: 3,529
Title: 21
Abstract: 358
References: 37
Figures: 4
Tables: 2
Supplementary tables: 7
Supplementary

figures:

1

## 1 Abstract

# 2 Background

Treatment with monoclonal antibodies against amyloid-β slowed cognitive decline in recent randomized
clinical trials in patients with mild cognitive impairment (MCI) and early dementia due to Alzheimer's
disease (AD). However, stringent trial eligibility criteria may affect generalizability of these findings to
clinical practice.

7

# 8 Methods

9 We extracted eligibility criteria for trials of aducanumab, lecanemab and donanemab from published 10 reports, and applied these to participants with MCI or early clinical AD dementia from the population-11 based Rotterdam Study. Participants underwent questionnaires, genotyping, brain MRI, cognitive testing, 12 and cardiovascular assessment. We had continuous linkage with medical records and pharmacy 13 dispensary data. We determined amyloid status using an established and validated prediction model 14 based on age and *APOE* genotype. We assessed progression to dementia within 5 years among 15 participants with MCI, stratified for eligibility.

16

### 17 Results

18 Of 968 participants (mean age: 75 years, 56% women), 779 had MCI and 189 early clinical AD dementia. 19 Across the three drug trials, around 40% of participants would be ineligible because of predicted amyloid 20 negativity. At least one clinical exclusion criterion was present in 76.3% (95% Cl; 73.3-79.3) of 21 participants for aducanumab, 75.8% (73.0-78.7) for lecanemab, and 59.8% (56.4–63.3) for donanemab. 22 Criteria that most often led to exclusion were a history of cardiovascular disease (35.2%), use of 23 anticoagulant (31.2%), use of psychotropic or immunological medications (20.4%), history of anxiety or 24 depression (15.9%), or lack of social support (15.6%). One-third of participants were ineligible based on 25 brain MRI findings alone, which was similar across trials and due predominantly to various 26 manifestations of cerebral small-vessel disease. Combining amyloid, clinical, and imaging criteria, 27 eligibility ranged from 9% (7.0-11.1) for aducanumab, 8% (6.2-9.9) lecanemab to 15% (12.4-17.5) for 28 donanemab. Risk of progression to dementia tended to be higher for ineligible than for eligible 29 participants for lecanemab (hazard ratio [95%CI]: 1.64 [0.92-2.91]), aducanumab (HR: 1.17 [0.65-2.12]), and only marginally for donanemab (HR: 1.03 [0.67-1.59]). 30

31

#### 32 Conclusions

- 33 Findings from recent RCTs reporting protective effects of monoclonal antibodies against amyloid-β are
- 34 applicable to less than 15% of community-dwelling individuals with MCI or early AD. These findings
- 35 underline that evidence for drug efficacy and safety is lacking for the vast majority of patients with
- 36 MCI/AD in routine clinical practice.

#### 37 Introduction

Alzheimer's disease (AD) is the leading cause of dementia, contributing to 38 million cases worldwide.<sup>1</sup> 38 39 The search for disease modifying therapy against AD has long been fruitless, with disappointing results from various trials aimed predominantly at the removal of cerebral  $\beta$ -amyloid depositions.<sup>2</sup> Since 2021, 40 41 however, three randomized clinical trials of monoclonal antibodies against  $\beta$ -amyloid have shown 42 slowing of cognitive and functional decline in patients with mild cognitive impairment (MCI) and earlystage AD dementia.<sup>3-5</sup> This led to the conditional approval of aducanumab (June 2021) and regular 43 44 approval of lecanemab by the United States Food and Drug Administration (FDA, July 2023) and the Japanese New Drug Application (September 2023) as the first disease-modifying therapies.<sup>6-8</sup> 45 Donanemab has been filed for approval, and a decision by the European Medical Association (EMA) on 46 lecanemab is pending.<sup>9,10</sup> The approval of these monoclonal antibodies against  $\beta$ -amyloid for clinical use 47 48 raises the question to which extent findings from trials are generalizable to the wider patient population, 49 in terms of both efficacy and safety.<sup>11</sup>

50

51 With regard to efficacy, external validity is of particular relevance for trials against AD, as dementia in the general population is often due to mixed pathology, and roughly half of the explained variance in clinical 52 syndromes of AD dementia is not due to AD-related pathological indices.<sup>12</sup> Efficacy in patients with pure 53 54 AD may not apply to patients with comorbid pathology, if the latter did not take part in clinical trials. 55 Indeed, trial eligibility criteria for AD trials preclude certain groups of patients, with criteria ranging from 56 restrictions in age to various types of comorbidities, medication use, and evidence of vascular brain 57 injury on magnetic resonance imaging (MRI). Similarly for safety, restriction of trial enrolment to patients 58 with relatively little comorbidity may underestimate occurrence of adverse effects, like amyloid-related 59 imaging abnormalities (ARIA), in the patient population seen in routine practice.

60

61 Three studies have thus far investigated external validity of Alzheimer trials in specialised memory clinic 62 populations. Applying eligibility criteria of aducanumab and lecanemab to these patient populations in Italy and Ireland, 73-99% of participants would have been ineligible for trial inclusion.<sup>13-15</sup> Similarly, two 63 64 studies using medical claims data in the United States of America found that over 90% would have been excluded from participation in trials of amyloid-lowering therapy.<sup>16,17</sup> Population-representative data of 65 66 European patients are lacking. Moreover, the largest clinical benefit to date has been observed for donanemab in the TRAILBLAZER-ALZ2 trial, but no published studies have yet examined the impact of 67 donanemab trial eligibility on external validity in the general population with MCI and AD dementia.<sup>5</sup> 68

- 69
- 70 In this study, we aimed to assess generalizability of trials of efficacious amyloid-lowering drugs by
- 71 applying trial eligibility criteria to participants with MCI and early dementia due to AD in the population-
- 72 based

Rotterdam

Study.

73

## 74 Methods

### 75 Selection of Trials

On august 14<sup>th</sup> 2023, we searched the literature for published phase 3 trials of monoclonal antibodies against β-amyloid that met their primary outcome for reducing cognitive and functional decline. Trials included were EMERGE (the high-dose arm of aducanumab), CLARITY-AD (lecanemab), and TRAILBLAZER-ALZ2 (donanemab). Details of included trials are presented in Supplementary Table 1. Trial inclusion and exclusion criteria were obtained from ClinicalTrials.gov and the original trial publications.<sup>3-5</sup> In case of discrepancy between ClinicalTrials.gov and the published report, we selected criteria from the latter.

83

### 84 Study Population to assess generalizability of trial findings

85 The Rotterdam Study is an ongoing population-based cohort study investigating determinants and 86 occurrence of disease in persons aged 40 years and older. The study started in 1990 and now comprises 87 17,931 individuals living in the Ommoord suburb of Rotterdam, the Netherlands. The design of the Rotterdam Study has been described in detail previously.<sup>18</sup> In brief, participants are invited for interview 88 89 and extensive in-person examination at a dedicated research centre every 3-6 years. Routine 90 examinations as part of the Rotterdam Study protocol include standardised questionnaires (e.g., social 91 support, mental health, medication use), cognitive assessment, cardiovascular exams (e.g., blood 92 pressure measurement, electrocardiogram and cardiac ultrasound), psychiatric assessment, 93 venepuncture, and genotyping. From 2005 onward, brain MRI became part of the core study protocol of 94 the Rotterdam Study. For the current study, we included all 968 participants who were diagnosed with 95 MCI (n=779) or early dementia due to clinical manifestation of AD (n=189) during the fourth (2002-2005) 96 and fifth (2009-2013) examination cycle of the study. Participants with dementia included in the current 97 study had to have a dementia diagnosis within 1 year from their study centre visit. From 2005 onwards 98 MRI of the brain was implemented into the core protocol of the Rotterdam Study. In total, 255/454 99 participants with MCI or early dementia due to AD from the fifth examination round had brain MRI scan 100 available.

101 The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 102 Medical Centre and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the 103 Population Studies Act for the Rotterdam Study. All participants provided written informed consent for 104 participation in the study, including permission to obtain information from their treating physicians.

#### 105

# 106 Ascertainment of mild cognitive impairment and dementia

107 Participants were screened for dementia at baseline and every 3-6 years during follow-up examinations 108 using the Mini-Mental State Examination (MMSE) and the Geriatric Mental Schedule (GMS) organic level. 109 Those with a MMSE score of <26 or a GMS organic level score of >0 were further examined using the 110 Cambridge Examination for Mental Disorders of the Elderly . Additionally, participants were continuously 111 under surveillance for incident dementia through the electronic linkage between the study database and 112 medical records from general practitioners and the Regional Institute of Outpatients Mental Health Care. 113 The general practitioner functions as a gatekeeper within the Dutch healthcare system, receiving written 114 information of any medical specialists' consultations of their patients. The final diagnosis of dementia 115 and its most common subtypes was made by a consensus panel led by a neurologist based on the 116 standard criteria for all-cause dementia (DSM-III-R) and clinical Alzheimer's disease (NINCDS-ADRDA). 117 Follow-up for dementia was completed until January 1, 2020.

Criteria for MCI were based on the Petersen criteria, and included the presence of subjective 118 cognitive complaints and objective cognitive impairment, in the absence of dementia.<sup>19</sup> A detailed 119 description of our MCI assessment has been published previously.<sup>20</sup> Subjective cognitive complaints 120 121 were evaluated by interview, including questions on memory and everyday functioning. We assessed 122 objective cognitive impairment using a cognitive test battery comprising the letter-digit substitution task, 123 Stroop test, verbal fluency test (animal categories), and 15-word verbal learning test based on Rey's recall of words.<sup>21</sup> Compound scores were constructed for various cognitive domains, including memory 124 function, information-processing speed, and executive function.<sup>21,22</sup> We classified persons as objectively 125 126 cognitively impaired if in any of the cognitive domains, the compound score was at least 1.5 standard 127 deviation lower than expected based on age and education adjusted means, derived from the study 128 population.

129

### 130 Operationalization of Trial Eligibility Criteria

For each of the trial inclusion and exclusion criteria, we defined an operationalization in the Rotterdam Study. This was done through consensus discussion between two authors (JJC and FJW). A detailed description of the eligibility criteria for each of the three trials, and their operationalization, is provided in Supplementary Tables 2, 3 and 4. For example, history of cardiovascular disease was based on a combination in-person assessment and continuous linkage with medical records for various

136 comorbidities, use of medication was assessed based on pharmacy dispensary data (ATC-codes), and we

137 had in-person questionnaires for social support and screening for anxiety and depression.

138

139 Brain magnetic resonance imaging

140 Participants underwent scanning on a 1.5-T MRI scanner (GE Healthcare) using a multisequence protocol 141 consisting of T1-weighted, proton density-weighted, fluid-attenuated inversion recovery, and T2weighted sequences. For brain volumetry, T1-weighted (voxel size  $0.49 \times 0.49 \times 1.6$  mm<sup>3</sup>), proton 142 143 density-weighted (voxel size  $0.6 \times 0.98 \times 1.6 \text{ mm}^3$ ), and the fluid-attenuated inversion recovery (FLAIR) 144 (voxel size  $0.78 \times 1.12 \times 2.5 \text{ mm}^3$ ) scans were used for automated segmentation of brain tissues, including white matter hyperintensities.<sup>23,24</sup> In short, a k-nearest neighbor tissue classification algorithm 145 was implemented for quantification of white matter hyperintensities (WMH).<sup>24</sup> All segmentations were 146 visually inspected, and manually corrected if needed. Severe WMH were defined as a volume of 16.1 147 milliliter or more, corresponding to a Fazekas score of 3.<sup>25,26</sup> All scans were appraised by trained research 148 physicians for the presence of cerebral microbleeds (i.e., small round to ovoid hypointense areas on T2\*-149 weighted images), lacunes (i.e., focal cavitating lesions  $\geq$ 3 and <15 mm), and cortical infarcts.<sup>27</sup> These 150 151 ratings were done blinded to clinical data. Furthermore, abnormalities including superficial siderosis, 152 intracranial aneurysms, meningioma, suspected gliomas, cavernous angioma, arachnoid cysts, arteriovenous malformations and dural fistulas were rated by research physicians, and subsequently 153 154 evaluated by a consultant neuroradiologist.

155

### 156 *Prediction of amyloid status*

To assess amyloid positivity, we used a prediction model based on age and *APOE*  $\varepsilon$ 4 allele count.<sup>28</sup> This model was developed within the Anti-Amyloid Treatment in Asymptomatic Alzheimer's trial population (A4 Study), and previously showed high discriminative ability to differentiate people with and without brain amyloid as measured by <sup>18</sup>F-florbetaben PET in the Rotterdam Study population (area under the curve: 0.84 [0.79–0.88]).<sup>28</sup>

162

#### 163 *Statistical analyses*

Missing data, most notably for social support (17.9%), Parkinson's disease (due to incomplete assessment of the Unified Parkinson Disease Rating Scale, 7.0%) and anxiety disorder (9.1%), were imputed using 5-fold multiple imputations ("mice" package in R). Details of all imputed variables are described in supplementary table 7.

For each trial, we determined the number of participants who met the eligibility criteria, both overall and per criterion separately. We compared the subset of trial eligible individuals to all individuals with MCl and early AD dementia in the population on several key demographics and participant characteristics, including, age, sex, educational attainment, MMSE, *APOE* ε4 carrier status, MCl or dementia status, cardiovascular disease and antithrombotic medication use. We repeated all analyses in the subsample (n=255) with brain MRI.

Finally, among all individuals with MCI in the primary analyses, we determined 5-year progression to dementia stratified by trial eligibility, by computing hazard ratios (HR) using Cox proportional hazard models.

177 All analyses were performed in R (version 4.2.1). This study is reported according to the 178 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.<sup>29</sup>

#### 179 Results

## 180 Study population

Overall, 968 participants were diagnosed with MCI or early dementia (mean age 75.1 years, 55.2% women), of whom 779 (80.5%) had MCI and 189 (19.5%) clinical AD dementia. Of these, trial-specific entry scores on the MMSE were met by 751 (77.6%) participants for aducanumab (MMSE  $\geq$ 24), 856 (88.4%) for lecanemab (MMSE  $\geq$ 22) and 762 (78.7%) for donanemab (MMSE 22-28). Mean (±SD) age of MMSE-eligible participants was similar across trials, varying from 74.0 (±8.0) years for aducanumab, to 74.5 (±8.1) for lecanemab and 75.3 (±8.1) years for donanemab. Little over half of participants were women for all three trials (51.6-55.6%).

188

# 189 Trial eligibility criteria

190 Trial eligibility criteria for EMERGE (aducanumab), CLARITY-AD (lecanemab), and TRAILBLAZER-ALZ2 191 (donanemab) are listed in supplementary tables 2, 3 and 4. Overall, TRAILBLAZER-ALZ2 listed the fewest 192 exclusion criteria. EMERGE was the only trial to exclude persons using platelet inhibiting or anticoagulant 193 medication. CLARITY-AD only included patients with objective impairment in episodic memory, whereas 194 the other two trials did not specify the affected cognitive domain among their inclusion criteria. All trials 195 excluded patients with severe small vessel disease on brain MRI (i.e., severe white matter hyperintensities or >4 microbleeds). EMERGE and CLARITY-AD additionally excluded patients with 196 197 lacunes or cortical infarct. CLARITY-AD further excluded individuals with intracranial aneurysms, 198 meningioma, cavernous angioma, and arachnoid cysts. A potentially eligible participant has to go 199 through eight different modalities, including cognitive testing, assessment of prior medical history and 200 comedication, BMI measurement, venepuncture, blood pressure measurement, electrocardiogram, 201 brain MRI scan and amyloid-PET scan or lumbar puncture, as well as have an informant/care partner 202 present for the duration of the study.

203

## 204 Eligibility on the basis of clinical criteria

Around two-thirds of participants met at least one clinical exclusion criterion, somewhat higher for aducanumab (76.3%; 95% Cl 73.3-79.3) and lecanemab (75.8%; 73.0-78.7) than for donanemab (59.8%; 56.4–63.3) (Figure 1, Supplementary Table 5). Compared to all individuals with MCl and early AD dementia in the Rotterdam Study, eligible participants were similar with respect to age, sex, educational attainment, *APOE*  $\varepsilon$ 4 carrier status (Table 1). MMSE scores at diagnosis were also similar between groups, although eligible participants were slightly more often at the MCl stage rather than having early

dementia. Those eligible for donanemab had more cardiovascular disease (18.3%) compared to those
eligible for donanemab (16.4%) and aducanumab (10.1%).

213

214 Overall, exclusion criteria related to cardiovascular comorbidity had the largest effect on trial eligibility, 215 but its impact differed between trials (Table 1 and Figure 1). For aducanumab, 264/751 (35.2%) 216 participants were excluded because of cardiovascular disease, and 234/751 (31.2%, mostly overlapping) 217 due to use of anticoagulant medication. Cardiovascular disease amounted to 10.7% exclusion of 218 participants for lecanemab and 9.7% for donanemab. Neurological comorbidity and lack of social 219 support were common reasons for ineligibility across trials, affecting 13.2 to 15.6% of potential 220 participants. In trials of lecanemab and donanemab, 16% of people were ineligible based on indication 221 of presence of mental health disorders, due chiefly to positive screening for depression or anxiety 222 disorder. Psychotropic or immunological medication use frequently led to exclusions for aducanumab 223 (20.4%), while for lecanemab only 0.8% met trial-specific exclusions for immunological medication, and 224 donanemab had no such exclusions.

225

Figure 3 shows the overlap between the different exclusion criteria within participants. Around one third of exclusion criteria across trials occurred in isolation (34% aducanumab, 41% lecanemab, 38% donanemab), as illustrated by the single, unconnected dots in Figure 3. Two thirds of participants who were ineligible due to cardiovascular disease also met one or multiple other exclusion criteria, similar across trials (Figure 3). A notable exception is the presence of non-amnestic MCl (in the absence of memory impairment), which was a common exclusion criterion for lecanemab (391/856, 45.2%), and occurred in isolation in over half of participants meeting this criterion (202/391; 51.7%) (Figure 3).

233

234 Impact of (predicted) amyloid positivity

235 Amyloid status was predicted negative in around 40% of all participants with MCI and early clinical AD 236 dementia, similar across trials (aducanumab 42.3%, lecanemab 40.4%, donanemab 37.9%). When adding 237 amyloid negativity to the aforementioned clinical eligibility criteria, the percentage of persons who were 238 ineligible increased from 76.3 to 88.4% for aducanumab, from 75.8 to 86.0% for lecanemab, and from 239 62.3 to 76.4% for donanemab. Conversely, among all age and MMSE eligible Rotterdam Study 240 participants with positive predicted amyloid status, application of clinical exclusion criteria left 73.8% of 241 participants ineligible for aducanumab, 78.2% for lecanemab, and 49.5% ineligible for donanemab 242 (Figure 2 and Supplementary Table 6).

#### 243

# 244 MRI criteria

Of all 968 included participants, 255 had an available brain MRI scan close to MCI/early AD diagnosis (mean interval: 2.3 years). The most common imaging abnormalities were of presumed vascular nature, with severe white matter hyperintensities in 24.6%, cortical infarcts in 10.6%, ≥2 lacunes in 7.5%, and >4 microbleeds in 3.1% of participants. Around one third of participants would be ineligible for trial participation on the basis of imaging criteria alone, which was similar across trials (Figure 4).

250

Eligibility based on clinical criteria was similar in the MRI subsample compared to the overall sample. Compared to the entire sample, participants who were eligible based on clinical and MRI criteria were slightly younger, less educated and more often carrier of the *APOE*  $\varepsilon$ 4 allele (Table 2). A combination of all clinical criteria, MRI criteria, and predicted amyloid negativity resulted in trial ineligibility of 91.1% (95% Cl, 88.9-93.0) for aducanumab, 91.6% (90.1-93.8) for lecanemab and 85.2% (82.5-87.6) for donanemab.

257

# 258 Dementia progression

During 5-year follow-up, progression to dementia was observed in 91 Rotterdam Study participants with
MCI. Participants with MCI who were ineligible based on clinical criteria tended to have higher risk of
progressing to dementia than eligible participants for lecanemab (HR: 1.64, 95% CI: 0.92 – 2.91),
aducanumab (HR: 1.17, 95% CI: 0.65 – 2.12) and only marginally for donanemab (HR: 1.03, 95% CI: 0.67
-1.59).

#### 264 Discussion

In this population-based study, findings from recent RCTs of monoclonal antibodies against amyloid-β are applicable to less than 15% of persons with MCl and early clinical AD dementia. This percentage was somewhat higher for donanemab (15%) than for aducanumab and lecanemab (8-9%). Trial ineligibility was commonly due to comorbid vascular pathology, either clinically or on brain MRI, neurological or psychiatric comorbidity, lack of social support, and concurrent anticoagulant or psychotropic medication use.

271

Thus far, no published studies have assessed eligibility criteria for the TRAILBLAZER-ALZ2 trial of donanemab, which had somewhat less stringent criteria compared to aducanumab and lecanemab. Eligibility for donanemab is slightly higher compared to aducanumab and lecanemab, due to more liberal inclusion of patients with cardiovascular comorbidity, but still limited at 15%. The observed eligibility of around 10% for aducanumab and lecanemab in this population-representative European sample is in accordance with two previous population-based studies from the United States.<sup>16,17</sup> Clinic-based studies from Italy and Ireland reported eligibility between 1% and 27%.<sup>13-15</sup>

Ineligibility in our study, as in previous reports, was mainly due to comorbid cardiovascular and cerebrovascular disease.<sup>16,17</sup> The limited inclusion of patients with vascular comorbidity underlines the need for caution and careful monitoring of drug safety if prescribing anti-amyloid-β antibodies to a yet untested patient population. Moreover, in patients with a combination of AD and vascular disease, cognitive impairment is often in part a consequence of cerebrovascular pathology,<sup>30</sup> and observed efficacy of monoclonal antibodies against amyloid-β in patients with relatively pure AD may not apply to those individuals.

286

Stringent eligibility criteria in AD trials serve in part to reduce safety and tolerability concerns.<sup>15</sup> Patients 287 288 excluded from clinical trials, particularly those with cardiovascular comorbidity, may face a conceivably 289 higher risk of side effects and adverse events. Although individuals using antithrombotic medications did not demonstrate an elevated risk of ARIA in the trial of lecenamab,<sup>31</sup> these findings might not apply to 290 291 non-participants with higher frailty or cardiovascular comorbidity. Moreover, any benefits of monoclonal 292 antibodies against cognitive decline in patients with AD who are at high risk of ischemic stroke, should be 293 carefully weighed against the contraindication for intravenous tissue plasminogen activator in the event of a stroke whilst on monoclonal antibodies against amyloid- $\beta$ .<sup>32</sup> Risk of ARIA is especially high in 294 295 homozygote APOE ɛ4 carriers, which prompts special consideration for this group in the FDA's

appropriate use criteria of lecanemab.<sup>33,34</sup> In our overall study sample, *APOE*  $\epsilon$ 4 carriership was somewhat lower than in clinical trials and a prior eligibility study from the U.S.,<sup>3-5,17</sup> but among those with predicted amyloid positivity, *APOE*  $\epsilon$ 4 carriership was consistent at around 80%.

299

300 At present, a large number of patients with cognitive impairment defers from seeking medical attention 301 until a fairly advanced stage of the disease. With the clinical availability of medication against AD, it is 302 expected that a substantial number of people with MCI will attend their physician sooner, in the hope of 303 disease-modifying treatment. Adequate preparation is imperative, and includes the necessary 304 diagnostics for determining amyloid status, monitoring safety, and estimating the contribution of amyloid – relative to other contributing causes – to cognitive decline within a single patient.<sup>35,36</sup> The 305 current study, along with the representative sample of U.S. citizens,<sup>17</sup> offers guidance as to the group of 306 307 patients for which there is some evidence of treatment efficacy, and those for which there is none as of 308 yet. Even if treatment labels would strictly follow trial eligibility criteria, the absolute number of patients 309 eligible for treatment will pose a challenge to healthcare systems.

310

The current study is strengthened by its large, population representative sample with detailed 311 312 information of demographics, clinical characteristics, and brain imaging. When interpreting our findings, however, some limitations need to be acknowledged. First, brain MRI was available only in a subsample 313 314 of the Rotterdam Study cohort. The applied prediction algorithm for amyloid positivity may have led to 315 some misclassification of amyloid status. However, the prediction algorithm was derived externally and validation in the Rotterdam Study population (using amyloid-PET) achieved high discriminatory value.<sup>28</sup> 316 317 Amyloid-PET is available in a subsample of the Rotterdam Study, but included only seven and thus too 318 few participants with MCI and early dementia to compute meaningful eligibility numbers. Second, 319 operationalization of the eligibility criteria in the Rotterdam Study was at times intrinsically hard to 320 define (e.g., "the participants need to be in good health as determined by the investigator"), or -321 incidentally- unavailable in the Rotterdam Study (i.e., childbearing potential and sensitivity to PET 322 tracers). Furthermore, availability of an informant/caregiver in the Rotterdam Study might differ from 323 that in clinical practice. Third, we did not include persons who developed dementia within the study 324 period but did not attend the research centre within 1 year from diagnosis. This might have led to some 325 underestimation of ineligibility, as these persons were older and most likely had more comorbid 326 pathology or were "not in good health as determined by the investigator". Last, the Rotterdam Study

- 327 consists of a predominantly White population, and generalizability to non-White populations remains to
- 328 be determined.<sup>37</sup>
- 329
- 330 In conclusion, findings from recent RCTs reporting protective effects of monoclonal antibodies against
- amyloid- $\beta$  are applicable to less than 15% of community-dwelling individuals with MCI or early AD. These
- findings underline that evidence for drug efficacy and safety is still lacking for the majority of patients
- with AD in the community.

```
334
```

# 335 References

336 Gauthier S R-NP, Morais JA, Webster C. World Alzheimer Report 2021: Journey through the 1. 337 Diagnosis of Dementia, 2021. 338 Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development 2. 339 pipeline: 2023. Alzheimers Dement (N Y) 2023; 9(2): e12385. 340 3. Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab 341 in Early Alzheimer's Disease. J Prev Alzheimers Dis 2022; 9(2): 197-210. 342 van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med 4. 343 2023; 388(1): 9-21. 344 5. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The 345 TRAILBLAZER-ALZ 2 Randomized Clinical Trial. Jama 2023; **330**(6): 512-27. 346 FDA Grants Accelerated Approval for Alzheimer's Drug. https://www.fda.gov/news-events/press-6. 347 announcements/fda-grants-accelerated-approval-alzheimers-drug (accessed 02-28 2024). 348 7. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval. 349 https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-350 treatment-traditional-approval (accessed 02-28 2024). 351 8. US E. LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer's 352 Disease in Japan 2023. https://us.eisai.com/press-releases/legembi-intravenous-infusion-lecanemab-353 approved-for-the-treatment-of-alzheimers-disease-in-354 japan#:~:text=%E2%80%9CToday%20LEQEMBI%20received%20approval%2C%20making,of%20the%20di 355 sease%20in%20Japan. (accessed 10-09 2023). 356 Wall JK. Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's 9. 357 Association Conference and Published in JAMA. https://investor.lilly.com/news-releases/news-release-358 details/results-lillys-landmark-phase-3-trial-donanemab-presented (accessed 02-28 2024). 359 10. Press release European Medicines Agency accepts Marketing Authorization Application for 360 lecanemab as treatment for early Alzheimer's disease. https://www.bioarctic.se/en/wp-361 content/uploads/sites/2/2023/01/bioarctic-european-medicines-agency-accepts-marketingauthorization-application-for-lecanemab-as-t-230126.pdf (accessed 02-28 2024). 362 363 11. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this 364 trial apply?". Lancet 2005; 365(9453): 82-93. 365 12. Boyle PA, Yu L, Leurgans SE, et al. Attributable risk of Alzheimer's dementia attributed to age-366 related neuropathologies. Ann Neurol 2019; 85(1): 114-24. 367 Togher Z, Dolphin H, Russell C, Ryan M, Kennelly SP, O'Dowd S. Potential eligibility for 13. 368 Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and 369 appropriate use criteria. Int J Geriatr Psychiatry 2022; 37(8). Padovani A, Caratozzolo S, Rozzini L, Pilotto A, Benussi A, Tedeschi G. "Real-world" eligibility for 370 14. 371 aducanumab depends on clinical setting and patients' journey. J Am Geriatr Soc 2022; 70(2): 626-8. 372 Canevelli M, Rossi PD, Astrone P, Consorti E, Vanacore N, Cesari M. "Real world" eligibility for 15. 373 aducanumab. J Am Geriatr Soc 2021; 69(10): 2995-8. 374 Anderson TS, Ayanian JZ, Souza J, Landon BE. Representativeness of Participants Eligible to Be 16. 375 Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries 376 With Alzheimer Disease and Mild Cognitive Impairment. Jama 2021; 326(16): 1627-9. 377 Pittock RR, Aakre J, Castillo AM, et al. Eligibility for Anti-Amyloid Treatment in a Population-17. 378 Based Study of Cognitive Aging. Neurology 2023.

379 18. Ikram MA, Brusselle G, Ghanbari M, et al. Objectives, design and main findings until 2020 from 380 the Rotterdam Study. Eur J Epidemiol 2020; 35(5): 483-517. 381 19. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch 382 *Neurol* 2005; **62**(7): 1160-3; discussion 7. 383 de Bruijn RF, Akoudad S, Cremers LG, et al. Determinants, MRI correlates, and prognosis of mild 20. 384 cognitive impairment: the Rotterdam Study. J Alzheimers Dis 2014; 42 Suppl 3: S239-49. 385 Bos D, Vernooij MW, Elias-Smale SE, et al. Atherosclerotic calcification relates to cognitive 21. 386 function and to brain changes on magnetic resonance imaging. *Alzheimers Dement* 2012; 8(5 Suppl): 387 S104-11. 388 22. Prins ND, van Dijk EJ, den Heijer T, et al. Cerebral small-vessel disease and decline in information 389 processing speed, executive function and memory. Brain 2005; **128**(Pt 9): 2034-41. 390 Vrooman HA, Cocosco CA, van der Lijn F, et al. Multi-spectral brain tissue segmentation using 23. 391 automatically trained k-Nearest-Neighbor classification. *Neuroimage* 2007; **37**(1): 71-81. 392 24. de Boer R, Vrooman HA, van der Lijn F, et al. White matter lesion extension to automatic brain 393 tissue segmentation on MRI. Neuroimage 2009; 45(4): 1151-61. 394 Andere A, Jindal G, Molino J, et al. Volumetric White Matter Hyperintensity Ranges Correspond 25. 395 to Fazekas Scores on Brain MRI. J Stroke Cerebrovasc Dis 2022; 31(4): 106333. 396 26. Joo L, Shim WH, Suh CH, et al. Diagnostic performance of deep learning-based automatic white 397 matter hyperintensity segmentation for classification of the Fazekas scale and differentiation of 398 subcortical vascular dementia. *PLoS One* 2022; **17**(9): e0274562. 399 27. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel 400 disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; **12**(8): 822-38. 401 28. Nguyen Ho PT, van Arendonk J, Steketee RME, et al. Predicting amyloid-beta pathology in the 402 general population. Alzheimers Dement 2023. 403 29. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in 404 Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bmj* 2007; **335**(7624): 405 806-8. 406 30. Boyle PA, Wang T, Yu L, et al. To what degree is late life cognitive decline driven by age-related 407 neuropathologies? Brain 2021; 144(7): 2166-75. 408 31. Marwan Sabbagh CHvD, Lawrence S. Honig, Jeffrey L. Cummings, Michelle Gee, Michio Kanekiyo, 409 Shobha Dhadd, Michael Irizarry, Lynn D. Krame. LECANEMAB PHASE 3 CLARITY AD TRIAL: ARIA WITH THE 410 USE OF ANTIPLATELETS OR ANTICOAGULANTS in EARLY ALZHEIMER'S DISEASE. 2023. 411 https://www.bioarctic.se/sv/wp-content/uploads/sites/4/2023/04/ARIA-and-Anticoagulation-412 Antiplatelet-ADPD2023.pdf (accessed 02-28 2024). 413 32. Reish NJ, Jamshidi P, Stamm B, et al. Multiple Cerebral Hemorrhages in a Patient Receiving 414 Lecanemab and Treated with t-PA for Stroke. N Engl J Med 2023; 388(5): 478-9. 415 33. Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate Use Recommendations. 416 J Prev Alzheimers Dis 2023; 10(3): 362-77. 417 FDA. Highlights of prescribing information LEQEMBI®. 34. https://www.accessdata.fda.gov/drugsatfda\_docs/label/2023/761269Orig1s001lbl.pdf (accessed 2023-418 419 12-27 2023). 420 35. Belder CRS, Schott JM, Fox NC. Preparing for disease-modifying therapies in Alzheimer's disease. 421 Lancet Neurol 2023; 22(9): 782-3. 422 van den Berg E, Vernooij MW, Mattace-Raso FUS, Wolters FJ. Sharpening the tools for the 36. 423 assessment of vascular cognitive impairment. Alzheimers Dement 2023; 19(4): 1587-8. 424 Grill JD, Flournoy C, Dhadda S, et al. Eligibility Rates among Racially and Ethnically Diverse US 37. 425 Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab 426 and Elenbecestat in Early Alzheimer Disease. Ann Neurol 2024; 95(2): 288-98. 427

428 Figure 1. Prevalence of trial eligibility criteria among participants with mild cognitive impairment and early Alzheimer's Disease dementia in

# 429 the population-based Rotterdam Study

- 430 Legend: Trial eligibility criteria among participants with mild cognitive impairment and early Alzheimer's disease in aducanumab (EMERGE),
- 431 lecanemab (CLARITY-AD) and donanemab (TRAILBLAZER-ALZ2) trials. Percentages reflect the percentage of participants with individual eligibility

Any clinical criterion

No social support Psychiatric

Other medication use

Age outside trial range

Clotting or hepatological disorder

Cardiovascular

Neurological

Non-amnestic

Body mass index


Renal dysfunction Thyroid dysfunction

Cancer


Anticoagulant medication use

Legend


432 criterion, or any criterion.



Lecanemab – CLARITY-AD (N=856)



# Donanemab – TRAILBLAZER-ALZ2 (N=762)



	All participants	Aducanumab		Denenemet	
	(n=968)	Aducanumab	Lecanemab	Donanemab	
No. of participants within trial MMSE range		751	856	762	
N (%) eligible based on clinical criteria		178 (23.7)	207 (24.2)	306 (40.2)	
Age, mean (SD)	75.1 (8.3)	70.6 (6.7)	74.3 (8.3)	73.2 (6.8)	
Women, n (%)	534 (55.2)	90 (50.6)	124 (59.9)	161 (52.6)	
MMSE, mean (SD)	25.4 (3.3)	27.1 (1.7)	26.4 (2.2)	25.5 (2.2)	
Low educational attainment <sup>^</sup> , n (%)	180 (18.6)	22 (12.4)	40 (19.3)	54 (17.8)	
APOE ε4 carriers, n (%)	301 (32.1)	63 (35.6)	55 (27.2)	113 (37.5)	
Heterozygote	270 (28.8)	56 (31.6)	50 (24.8)	100 (33.2)	
Homozygote	31 (3.3)	7 (4.0)	5 (2.5)	13 (4.3)	
Cognitive impairment					
Mild cognitive impairment, n (%)	779 (80.5)	160 (89.9)	178 (86.0)	258 (84.3)	
Early dementia, n (%)	189 (19.5)	18 (10.1)	29 (14.0)	48 (15.7)	
Cardiovascular disease*, n (%)	266 (27.5)	18 (10.1)	34 (16.4)	56 (18.3)	
Antithrombotic medication use, n (%)	392 (40.5)	29 (16.3)	66 (31.2)	103 (33.7)	
Antiplatelet	102 (10.5)	19 (10.7)	25 (12.1)	34 (11.1)	
Anticoagulant	290 (30.0)	0 (0.0)	41 (19.8)	69 (22.5)	

434	Table 1. Eligibility of all 968 participants with mild cognitive impairment and early Alzheimer's disease dementia in the	Rotterdam Study
-----	---------------------------------------------------------------------------------------------------------------------------	-----------------

435 Eligibility criteria as applied in the EMERGE trial for aducanumab, CLARITY-AD trial for lecanemab, and TRALBLAZER-ALZ2 trial for donanemab.

436 No., number; MMSE, Mini-Mental State Examination; SD, standard deviation.


437 \*indicates composite of previous transient ischemic attack, stroke, myocardial infarction, or coronary artery revascularization procedure.

438 ^indicates primary education only


439 Data were missing for level of education (0.9%) and *APOE* ε4 carriers (3.0%).

Figure 2. Prevalence of trial eligibility criteria among participants with positive predicted amyloid status and mild cognitive impairment or early Alzheimer's disease dementia in the population-based Rotterdam Study

- 442 Trial eligibility criteria among participants with mild cognitive impairment and early Alzheimer's disease in aducanumab (EMERGE), lecanemab
- 443 (CLARITY-AD) and donanemab (TRAILBLAZER-ALZ2) trials. Percentages reflect the percentage of participants with individual eligibility criterion, or
- 444 any criterion.




Lecanemab - CLARITY-AD (N=391)





Donanemab – TRAILBLAZER-ALZ2 (N=295)




medRxiv preprint doi: https://doi.org/10.1101/2024.02.29.24303553; this version posted February 29, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

446 Figure 3.

# 447 Title: Concurrence of eligibility criteria for aducanumab, lecanemab and donanemab

Legend: These intersection diagrams show the patterns of co-occurrence of different eligibility criteria. Rows represent the types of eligibility

- criteria and columns represent their combinations. All criteria that are part of a given combination are shown as black dots connected by a
- vertical black line. A single dot without a line implies the symptom occurred in isolation. The number of participants with a given combination of
- 451 criteria is shown as a vertical bar on top of the matrix. The graph is truncated at a minimum of four participants per combination.




453 BMI indicates body mass index.

# 454 Figure 4. Impact of MRI criteria on trial eligibility

455 Legend: Prevalence of trial eligibility criteria for brain magnetic resonance imaging (MRI) scan among participants with mild cognitive impairment

456 and Alzheimer's disease dementia in aducanumab (EMERGE), lecanemab (CLARITY-AD) and donanemab (TRAILBLAZER-ALZ2) trails. Percentages

457 reflect the percentage of participants with individual eligibility criterion, and MRI abnormalities reflect the presence of any of the MRI criteria.



Aducanumab – EMERGE (N=221)





	All participants	Aducanumab <sup>1</sup>	Lecanemab <sup>2</sup>	Donanemab <sup>3</sup>	
	(n=255)	Aducanumab	Lecanemab	Donanemab	
No. of participants with available MRI scan		N = 221	N = 239	N = 209	
N (%) eligible based on MRI criteria		158 (71.5)	159 (66.5)	152 (72.7)	
N (%) eligible based on clinical + MRI criteria		49 (22.2)	39 (16.3)	64 (30.6)	
Age, mean (SD)	74.0 (7.3)	70.0 (6.4)	69.6 (6.7)	71.5 (5.9)	
Women, n (%)	113 (44.3)	24 (49.0)	18 (46.2)	29 (45.3)	
MMSE, mean (SD)	26.3 (2.4)	26.9 (1.6)	26.9 (1.5)	26.2 (1.8)	
Low educational attainment, n (%)	33 (13.0)	6 (12.2)	7 (17.9)	10 (15.6)	
APOE ε4 carriers, n (%)	76 (30.6)	19 (38.7)	15 (39.5)	26 (41.3)	
Heterozygote	68 (27.4)	17 (34.7)	14 (36.8)	25 (39.7)	
Homozygote	8 (3.2)	2 (4.1)	1 (2.6)	1 (1.6)	
Cognitive impairment					
Mild cognitive impairment, n (%)	228 (89.4)	45 (91.8)	37 (94.9)	57 (89.1)	
Early clinical AD dementia, n (%)	27 (10.6)	4 (8.2)	2 (5.1)	7 (10.9)	
Cardiovascular diseaseˆ, n (%)	74 (29.0)	7 (14.3)	4 (10.3)	8 (12.5)	
Antithrombotic medication use, n (%)	113 (44.3)	9 (18.4)	8 (20.5)	10 (16.5)	
Antiplatelet	34 (13.3)	9 (18.4)	7 (17.9)	9 (14.1)	
Anticoagulant	79 (31.0)	0 (0.0)	1 (2.6)	1 (1.6)	

460 Table 2. Baseline characteristics for the overall Rotterdam Study cohort with mild cognitive impairment and early Alzheimer's disease 461 dementia and according to their eligibility for published trials

462 <sup>1</sup> Eligibility criteria as applied in EMERGE trial. <sup>2</sup> Eligibility criteria as applied in CLARITY-AD trial. <sup>3</sup> Eligibility as applied in TRALBLAZER-ALZ2 trial.

463 No., number; MMSE, Mini-Mental State Examination; SD, standard deviation. ^indicates composite of previous transient ischemic attack, stroke,

464 myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting. Data were missing for level of education (0.8%)

465 and *APOE* ε4 carriers (2.7%).